Outlook Therapeutics (OTLK) Return on Capital Employed (2016 - 2026)
Outlook Therapeutics (OTLK) posted quarterly Return on Capital Employed of 321.89% for Q1 2026, down 80525.0% year-over-year from N/an in Q1 2025, and up 67.36% quarter-over-quarter from 192.33% in Q4 2025.
Outlook Therapeutics (OTLK) Return on Capital Employed (2016 - 2026) Analysis & Trends
Outlook Therapeutics (OTLK) has reported Return on Capital Employed for 11 consecutive years, with 321.89% the latest figure, recorded in Q1 2026.
- In Q1 2026, Return on Capital Employed fell 80525.0% year-over-year to 321.89%; the TTM figure through Mar 2026 stood at 321.89% (down 80525.0% YoY), while the FY2025 annual figure was 303.3%, down 29464.0% from the prior year.
- Return on Capital Employed rose to 321.89% in Q1 2026 per OTLK's latest filing, from 192.33% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 7870.81% in Q2 2023 and bottomed at 583.31% in Q2 2024.
- Historically, Return on Capital Employed has averaged 690.09% across 5 years, with a median of 264.79% in 2025.
- Annual changes were most pronounced in 2023 — Return on Capital Employed surged 805094 bps — and 2024, when it plunged 845412 bps.
- Outlook Therapeutics' Return on Capital Employed stood at 214.93% in 2022, then soared by 217 bps to 251.69% in 2023, then jumped by 30 bps to 327.72% in 2024, then tumbled by 41 bps to 192.33% in 2025, then soared by 67 bps to 321.89% in 2026.
- Business Quant data shows OTLK's Return on Capital Employed at 321.89% in Q1 2026, 192.33% in Q4 2025, and 264.79% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -38.20% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 13.68% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 26.09% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -6.85% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -50.93% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 7.88% |
| 10 | Outlook Therapeutics | 88.50 Mn | 77.26 Mn | -8,265.00 | 1,198.94% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 321.89% |
| Dec 31, 2025 | 192.33% |
| Sep 30, 2025 | 264.79% |
| Jun 30, 2025 | 675.22% |
| Mar 31, 2025 | 1,127.14% |
| Dec 31, 2024 | 327.72% |
| Sep 30, 2024 | 1,560.02% |
| Jun 30, 2024 | -583.31% |
| Mar 31, 2024 | 436.21% |
| Dec 31, 2023 | 251.69% |
| Sep 30, 2023 | 635.61% |
| Jun 30, 2023 | 7,870.81% |
| Mar 31, 2023 | -361.05% |
| Dec 31, 2022 | -214.93% |
| Sep 30, 2022 | -456.11% |
| Jun 30, 2022 | -180.13% |
| Mar 31, 2022 | -136.39% |
| Dec 31, 2021 | -164.58% |
| Sep 30, 2021 | -245.21% |
| Jun 30, 2021 | -249.53% |